done through patients' records and the national mortality registry. Results were analysed using Cox proportional-hazards models, Kaplan-Meier estimator and for repeated events the Anderson-Gill method, on an intention-to-treat and ontreatment basis. Results: Eighty-eight consecutive patients (median age 32 years, 57 males, 63 TGA) were followed for a median of 8.3 years since randomization. Use of cardiac drugs after trial closeout was similar in both randomization groups (49% β-blocker, 45% ARB/ACE-inhibitor, 30% antiarrhythmic, 22% diuretic). Six patients (n=3 valsartan, n=3 placebo) died, yielding a long-term survival of 90%. Mortality was predominantly a result of heart failure and sudden death, and higher among symptomatic (19%) than asymptomatic patients (2%, P=0.010). Fifty-three (60%) patients experienced events; supraventricular arrhythmia (n=40), ventricular arrhythmia (n=22), worsening heart failure (n=20), tricuspid valve surgery (n=6), and death (n=6). No difference in separate or the composite endpoint was found between the original valsartan and placebo groups, with corresponding eventfree survival rates of 50% and 34% at 8.3 years (P=0.120). Nevertheless, valsartan significantly reduced the risk for events in symptomatic patients (HR 0.37; 95% CI 0.14-0.92) though not in asymptomatic patients (HR 0.84; 95% CI 0.42-1.69, Figure) . Repeated event analysis and time-dependent analysis with posttrial ARB/ACE-inhibitor use did not alter results.
Background:
In patients with bicuspid aortic valve (BAV), the prevalence of BAV in first degree relatives (FDRs) has been assessed to be 8-10% and the occurrence of families with 2 or more affected members ("familial BAV") to be 28-37%. However, selection bias might have played a role as this was studied in tertiary centres. Purpose: To determine the prevalence of BAV in FDRs of patients with isolated BAV in a general hospital, together with the occurrence of aortic dilatation in these FDRs and the occurrence of "familial" BAV. Methods: From 2012, patients with BAV visiting the outpatient clinic, received written information for their FDRs that cardiac screening was advised. FDRs of patients with isolated BAV who responded, were included. Data of FDRs with already diagnosed BAV were traced to determine the occurrence of "familial BAV". Results: FDRs of 54 index patients with isolated BAV responded. The mean age of these index patients was 62 years (SD13, range 27-81 years), 33 (61%) were male and 36 (67%) had undergone aortic valve replacement, including concomitant ascending aorta replacement in 12 (22%). In the unoperated patients, 11 (20%) had aortic dilatation (>40mm): 2 at level of sinus of Valsalva, 1 at level of tubular ascending aorta. We screened 134 FDRs (average 2.5 per patient) who comprised 5 parents (3.7%), 52 siblings (39%) and 77 offspring (57%). Mean age of FDRs was 49 years (SD15, range 16-83 years) and 55 subjects (41%) were male. The imaging modality was echocardiography in 129 cases (96%) and MRI in 5 cases. In the 134 FDRs we diagnosed 8 new BAV belonging to 4 index patients. Of these new BAV patients, mean age was 40 years, 5 were male (63%) and 3 had aortic dilatation (>40mm). The prevalence was 6.0% (95% confidence interval [CI] 2.6-11.4%). (Figure) In the 126 FDRs without BAV, 10 FDRs (7.9%; 95% CI 3.9-13%) had aortic dilatation: 8 at level of sinus of Valsalva and 2 at level of tubular ascending aorta (4 with hypertension). Their mean age was 58 years, 60% were male. Additionally, we traced the data of 22 FDRs with an already known cardiac phenotype of whom 6 had BAV. (Figure) They belonged to 6 index patients. When added to the newly diagnosed BAVs, "familial BAV" was present in 17% (9 of 54 families,1 overlap). 
Conclusion:
Screening FDRs of patients with isolated BAV in a general hospital resulted in a somewhat lower prevalence (6.0%) of newly diagnosed BAV than earlier studies but with an additional yield of aortic dilatation without BAV (7.9%). For these reasons we conclude that also in a general hospital, family screening was beneficial.
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